Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Income towards Parent Company: 2021-2024

Historic Income towards Parent Company for Axsome Therapeutics (AXSM) over the last 4 years, with Dec 2024 value amounting to -$287.2 million.

  • Axsome Therapeutics' Income towards Parent Company rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.20%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
  • As of FY2024, Axsome Therapeutics' Income towards Parent Company stood at -$287.2 million, which was down 20.05% from -$239.2 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Income towards Parent Company high stood at -$130.4 million for FY2021, and its period low was -$287.2 million during FY2024.
  • Its 3-year average for Income towards Parent Company is -$237.9 million, with a median of -$239.2 million in 2023.
  • Data for Axsome Therapeutics' Income towards Parent Company shows a maximum YoY tumbled of 43.50% (in 2022) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Income towards Parent Company (Yearly) stood at -$130.4 million in 2021, then plummeted by 43.50% to -$187.1 million in 2022, then fell by 27.84% to -$239.2 million in 2023, then fell by 20.05% to -$287.2 million in 2024.